Purpose: To compare the intraocular pressure (IOP) response to a modified protocol for selective laser trabeculoplasty (SLT) to standard protocols for SLT and argon laser trabeculoplasty (ALT).
L
aser trabeculoplasty is an established clinical intervention to reduce intraocular pressure (IOP) in the management of open-angle glaucoma (OAG). Both argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) have been shown to have equal efficacy in short-term and long-term follow-up.
1,2 A recent randomized, controlled trial comparing ALT with SLT showed that the 2 are equivalent up to 1 year after intervention. 3 However, one of the advantages of SLT is the lack of coagulative damage and disruption of the corneoscleral or uveal trabecular meshwork, which has led investigators to postulate that SLT may be repeatable. 4 As SLT is a relatively new procedure, only a limited number of protocols have been evaluated in an attempt to determine the technique with the greatest efficacy. 5 For example, a comparison between application of SLT over 90 and 180 degrees using 25 nonoverlapping laser spots per quadrant showed no difference in the pressure response between the 2 techniques. 6 Other studies, however, demonstrated better response with increasing numbers of nonoverlapping spots 7 and success rates were shown to be better with 180 and 360-degree treatments rather than with 90 degrees of SLT application. 8 As SLT is not thought to cause any structural damage and thus may theoretically be overlapped to thoroughly cover the trabecular meshwork, we retrospectively evaluated the outcome of a modified protocol applying 100 overlapping SLT spots in 180 degrees of meshwork and compared it with a protocol applying 100 nonoverlapping SLT spots in 360 degrees and to a standard ALT protocol with 50 spots in 180 degrees. All the patients in the study were on treatment with one or more topical medications for their glaucoma before the laser trabeculoplasty. We further examined whether baseline IOP, the class and number of prelaser medications, central corneal thickness (CCT), lens status, and prior ALT predicted response to the respective laser intervention in each group and followed the patients for an average period of 14 months. Patients were excluded from further study after they underwent any subsequent IOP-lowering procedures, including trabeculectomy or repeat laser trabeculoplasty during the follow-up period. After obtaining approval from the Yale University School of Medicine Human Investigations Committee, the following information was recorded from each patient's chart: age, sex, race, visual acuity, type of glaucoma, phakic status, CCT, type of laser used for trabeculoplasty, number of spots, power and location of laser applications and whether the patient had previously received any type of laser intervention. The number and classes of medications used before and after the interventions were also noted. The average of 3 IOPs on 3 visits immediately before the laser procedure was used as the baseline pressure. Postoperative pressures and the number of medications were obtained on average at 1 hour, 6 weeks, 4 months, and 14 months.
SLT was performed with a 532-nm frequencydoubled, Q-switched Neodymium:Yttrium Aluminum Garnet (Nd:YAG) Coherent Selecta 7000 laser (Lumenis, Coherent Inc, Palo Alto, CA) with a pulse duration of 3 ns and spot size of 400 mm coupled to a slit lamp delivery system and a Helium-Neon aiming laser. After instilling a drop of topical anesthetic and an a-blocker, apraclonidine 0.5%, a goniolens was placed on the cornea. The pulse energy was initially set between 0.5 to 0.8 mJ and increased in 0.1 mJ increments until fine bubbles were noted on the meshwork. The energy was then decreased by 0.1 mJ for the rest of the applications. In the modified SLT protocol, laser spots were placed with 50% overlap of the previous application. The number of overlapping spots ranged from 64 to 149 (mean, 104 spots; SD = 18.67) in 180 degrees of trabecular meshwork and the pulse energy ranged from 0.5 to 1.6 mJ (mean, 1.03 mJ, SD = 0.17). Although the laser applications were invariably overlapping in nature, there were individual variations in the structure and accessibility to the angle especially in eyes that had undergone prior cataract surgery, which accounts for the range in the number of applied spots among patients in this group. Postoperatively, another drop of apraclonidine 0.5% was instilled and prednisolone acetate 1% drops were given 4 times a day for 5 days. In the nonoverlapping SLT group, the number of laser applications ranged from 76 to 139 (mean, 105 spots; SD = 12.83) in 360 degrees of meshwork and the energy ranged from 0.7 to 1.1 mJ (mean, 0.89 mJ; SD = 0.1). Postoperatively, diclofenac sodium 0.1% drops were given 4 times a day for 5 days. Patients who underwent ALT received the same prelaser regimen of topical anesthetic and apraclonidine 0.5% and the procedure was performed with argon blue-green (l = 488 to 514 nm) laser with settings of 50-mm spot size and 0.1-s pulse duration with 41 to 67 (mean, 54; SD = 5.8) spots in 180 degrees of trabecular meshwork. The average power ranged from 400 to 600 mW. Postoperatively, a drop of apraclonidine 0.5% was instilled and prednisolone acetate 1% was given 4 times a day for 5 days.
All statistical analyses were carried out using R (version 2.4.0; http://www.r-project.org) and SPSS 14.0 (SPSS, Chicago, IL). A responder was defined as a patient with a decrease in IOP of at least 3 mm Hg and 20% from baseline, without any additional laser or incisional surgical intervention. To identify factors associated with the fall in IOP, we explored regression models using the percentage and unit fall in IOP from baseline as the dependent variable. The number and type of prelaser medications, baseline IOP, CCT, prior ALT, pseudophakic status, the number of laser spots and power used were all considered as predictors in the model. The formal analysis was performed with multiple linear regression models to determine whether these preoperative factors predicted the percent reduction in IOP at 4 months after the surgery. We used the final regression results to compare the predicted changes in IOP across the 3 groups.
RESULTS
A total of 318 eyes of 284 patients were included in the regression analysis. Table 1 presents the baseline descriptive statistics of the 3 groups. A subset of patients in both the SLT treatment groups had received ALT in the past (38.2% in overlapping SLT and 18.4% in nonoverlapping SLT). Our analysis revealed no significant influence of prior ALT on subsequent IOP response in either SLT group. Similarly, the proportion of pseudophakic patients was comparable in both SLT groups (Table 1) , but significantly higher than in the ALT group. Again, pseudophakic status did not significantly influence fall in pressure in any of the groups. The number of medications before and after intervention was similar in the overlapping SLT and ALT groups at all follow-up times, whereas patients receiving nonoverlapping SLT showed a decrease in the mean number of medications (from 2.48 before intervention to 2.0 at 14-mo follow-up; P<0.001). Table 2 shows the percentage of patients with change in total number of medications at 4 and 14 months from baseline. There were fewer changes in number of medications early in the follow-up period and trends were similar throughout.
Patients receiving ALT had a higher mean baseline IOP than those receiving overlapping SLT (P = 0.013). The ALT group also differed from the 2 SLT groups in having no prior ALT, lower number of prelaser medications, lower proportion of pseudophakic eyes, and lower prostaglandin use. The 2 SLT groups, on the other hand, were very comparable at baseline and thus, validated the comparison between overlapping with nonoverlapping SLT.
At 4 months after the laser, 2 patients in the overlapping SLT group were lost to follow-up. Between the 4 and 14-month visits, 41% patients in the overlapping SLT group required additional IOP-lowering procedures (trabeculectomy, phacotrabeculectomy, repeat ALT, or SLT) compared with 17% in the nonoverlapping SLT group and 19% in the ALT group. At 14 months, 20.6% patients who received overlapping SLT were lost to follow-up, compared with 4.5% patients who received nonoverlapping SLT and 26% patients who received ALT, thus possibly precluding reliable results at 14 months. Consequently, our primary analysis focused on the outcomes at 4 months, although the results were found to be similar at all follow-up times.
Baseline IOP was strongly associated with and directly proportional to both percent and unit reduction in pressure after nonoverlapping SLT (P = 0.0019) and ALT (P<0.0001), but not after overlapping SLT (P = 0.6697). No other baseline variable was significantly associated with the IOP outcome in any treatment group. The mean drop in IOP was similar for nonoverlapping SLT and ALT, both of which were greater than that for overlapping SLT at 4 and 14-month follow-ups. Furthermore, the proportion of defined responders was comparable for nonoverlapping SLT and ALT at all follow-up times, whereas patients receiving overlapping SLT had a significantly smaller proportion of responders (Fig. 1) . Figure 2 , based on observed IOPs, shows the estimated percentage reductions in IOP over a range of baseline pressures for each of the treatment groups after intervention (Model R 2 = 0.149).
DISCUSSION
SLT was first described in 1995 by Latina and Park, 9 who reported that pigmented trabecular meshwork cells could be treated with pulsed lasers using lowthreshold radiant exposures, thereby avoiding collateral damage to adjacent nonpigmented cells. In a nonrandomized, prospective clinical trial, it was further shown that SLT is a safe and effective method to lower IOP in patients with OAG and in those with prior ALT. 10 A purported advantage of SLT over ALT is the lack of structural damage to the meshwork, which suggests the potential for repeatability of the laser procedure. SLT has been proposed as a primary intervention in the treatment of OAG 11 and a randomized, controlled trial showed that SLT was equally efficacious as latanoprost in reducing IOP in patients with newly diagnosed OAG or ocular hypertension for up to 12 months of follow-up. 12 SLT has also been shown to have a potential cost-saving effect over medical therapy in a projected 6-year comparison. 13 Although there has been increased utilization of laser trabeculoplasty since the introduction of SLT, 14 the optimum treatment protocol is yet to be established. 5 Following the introduction of ALT in the early 1980s, various protocols were evaluated before a standard protocol was widely adopted. 15 Similarly, a few protocols have been evaluated for SLT in the past. Chen et al 6 found that there was no difference in IOP outcome between 25 laser spots over 90 degrees of meshwork or 50 spots over 180 degrees. However, others have demonstrated that a greater number of laser applications spread over a larger circumference improved results. 8 To further evaluate the influence of the number of spots per area, we compared the outcome after 100 overlapping SLT spots in 180 degrees with that of 100 nonoverlapping SLT spots in 360 degrees and a standard ALT protocol and found that the modified overlapping SLT protocol did not perform as well as either of the latter 2 procedures.
Selective photothermolysis with frequency-doubled Q-switched Nd:YAG laser uses a pulse duration of 3 ns which is shorter than the thermal relaxation time of melanin (B1 ms). Consequently, the pigment molecule is selectively targeted leading to its expansion and subsequent cellular injury. 9 This selective targeting involves minimal mechanical and collateral damage to the meshwork compared with ALT. Pigmented trabecular meshwork cells, in vitro, seem to lose normal morphology and adherence about 8 hours after SLT application 9 and the threshold energy required to achieve this response is noted to decrease with increasing numbers of melanin particles within the cell. Using transmission and scanning demonstrated that the mechanical damage caused by SLT and ALT were comparable after 1 to 5 days in that both caused splitting and fragmentation of the trabecular beams but that the extent of damage was less after SLT. The mechanical effect of photodisruption has been previously proposed as a mechanism for IOP reduction within the first hour after SLT. 11 Loss of pigmented cells and ultrastructural fragmentation of the meshwork probably explains the poor outcome after SLT in heavily pigmented eyes and in cases with pigment dispersion. 18 Recent evidence by Wood et al 19 has shown that higher energy levels of SLT result in immediate vaporization of pigmented cells by necrosis over a period of 30 minutes to 12 hours immediately adjacent to the site of the laser treatment; and that, this was further followed by the delayed death by apoptosis of more outlying cells 2 to 10 days after treatment. The degree of both immediate and delayed cell death was directly related to the magnitude of the laser energy setting and the distance from the central irradiated zone. It is possible that the overlapping nature and increased density of laser applications and the higher mean energy used in the overlapping SLT protocol compared with the nonoverlapping group could have exacerbated this disruptive effect leading to the poorer outcome in our group of patients.
Other possible explanations for the difference in outcome between the 2 SLT protocols are the difference in areas treated and the 2 different postoperative medications used. Unlike previous studies that looked at dose response, we essentially compared the effect of applying a comparable number of spots over 180 and 360 degrees. Song et al 20 reported an overall failure rate of 68% to 75% with 50 nonoverlapping SLT spots over 180 degrees, which is similar to our finding of 65% to 70% failure rate with 100 overlapping spots over 180 degrees. It may be, therefore, that the area of SLT application is more important than the number of spots.
A proposed mechanism of action of SLT is an inflammatory response releasing cytokines interleukin-1a, interleukin-1b and tumor necrosis factor-a which in turn up-regulate macrophages in the trabecular meshwork. 4 SLT induces a low-grade inflammation in other parts of the meshwork through the spread of free radicals in the aqueous humor, 6 which is a result of increased lipid peroxide levels and decreased free-radical-scavenging superoxide dismutase and glutathione S transferase levels in the aqueous humor. 21 The concentrations of these enzymes have been shown to return to normal levels between 3 and 7 days after SLT without the aid of any anti-inflammatory agents. 21 Corticosteroids act by inhibiting phospholipase A2 and the subsequent formation of arachidonic acid, the substrate for both the cyclooxygenase and lipoxygenase pathways. The limited application of SLT to one half of the trabecular meshwork, along with a stronger suppression of inflammatory response with prednisolone in the overlapping SLT group could have led to the poorer outcome in contrast to those patients who received 360-degree SLT followed by diclofenac postoperatively. However, recent evidence by Realini et al 22 showed that suppressing inflammation with prednisolone acetate after SLT does not seem to diminish SLT's effect on IOP. This could lend further support to the hypothesis that the overlapping nature of the SLT application was the plausible cause for the poor results in that group.
A number of baseline factors have been linked with response to laser trabeculoplasty, including prior ALT, 23 pseudophakic status, [24] [25] [26] CCT, 27, 28 baseline IOP, 1, 20, 29 and the number of prelaser medications. Brooks and Gillies 30 found that baseline IOP and the type of glaucoma were the 2 main predictive factors for outcome after ALT. In our study, baseline IOP was not a significant predictor for response to overlapping SLT, but was highly significant for nonoverlapping SLT and ALT. We also found that prostaglandin therapy had a negative influence in patients who received nonoverlapping SLT over 360 degrees, although this did not reach statistical significance. Similar findings were reported in a previous retrospective study, 20 suggesting that the mechanism of pressure reduction by prostaglandins and SLT may share a common pathway.
The limitations of this study include its retrospective nature and the fact that the 2 SLT protocols were performed by 2 different surgeons, who used different postoperative anti-inflammatory agents. The changes in the postlaser IOP-lowering medications were made at the discretion of the treating surgeon in each group and consequently the fall in IOP may not be the only indicator of success after the intervention. However, only the nonoverlapping SLT group showed a statistically significant decrease in the mean number of IOP-lowering medications. There was also a difference in the percentage of patients who received prior ALT in the 2 SLT groups, although prior ALT did not appear as a significant variable for SLT outcome in the regression model.
In conclusion, overlapping SLT with 100 spots over 180 degrees leads to a poorer response compared with nonoverlapping SLT with 100 spots over 360 degrees. The latter was comparable with ALT at all follow-up times. Baseline IOP was the only significant factor, which positively influenced response to ALT and nonoverlapping SLT.
